What the business is, and whether it's a good one at a fair price.
Manufactures IV fluid bottles and Small Volume Parenterals (SVP) for pharmaceutical and healthcare use. The SteriPort range uses ISBM (Injection Stretch Blow Moulding) technology to make two-port IV fluid bottles and contributes 42% of FY26 revenue; a third SteriPort line is being commissioned to roughly double annual capacity. The SVP portfolio covers inhalation and ophthalmic products. Materials are the largest cost line at 33.7% of revenue, with polymer price increases of 60-70% passed through via 5-6% selling price increases. FY26 revenue stood at INR288 crore with EBITDA of INR63 crore (22% margin) and PAT of INR15 crore.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AMANTA HEALTHCARE LIMITED's filed financials and exchange disclosures
AMANTA HEALTHCARE LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AMANTA.
Yes. Over the trailing twelve months AMANTA HEALTHCARE LIMITED reported a net profit of ₹15 Cr on revenue of ₹291 Cr.
Yes. The dividend yield is 0.05% at the current price. It paid out 3% of its profit as dividend in FY26.
No. Debt stands at 1.06× equity, and it carries net debt of ₹153 Cr. That is lower than 6% of its 171 Pharmaceuticals peers.
On trailing P/E, AMANTA HEALTHCARE LIMITED ranks 129 of 169 in Pharmaceuticals — cheaper than 24% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AMANTA HEALTHCARE LIMITED moves 1.97% — that is the median absolute close-to-close move across its last 249 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AMANTA HEALTHCARE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
